Clinical trial
Rituximab in the Treatment of Patients With Bullous Pemphigoid
NCT00286325 · Duke University, Other · Completed
Key facts
| NCT number | NCT00286325 |
|---|---|
| Title | Rituximab in the Treatment of Patients With Bullous Pemphigoid |
| Official title | Rituximab in the Treatment of Patients With Bullous Pemphigoid |
| Lead sponsor | Duke University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Bullous Pemphigoid |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 8 |
| Start date | Mar 1, 2005 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Feb 3, 2006 |
| Last update posted | Apr 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: